The Rohatyn Group Agrees to Sell Leading Omni Channel Pet Care Platform Pet Network International to A&M Capital Europe
The Rohatyn Group (“TRG”), a global, US-based asset management firm with expertise in emerging markets and real assets, and A&M Capital Europe (“AMCE”), a London-based, operationally-focused European middle-market private equity firm, today announced that they have entered into a definitive agreement under which TRG will sell Pet Network International d.o.o. (“Pet Network” or “the Company”) to AMCE. Pet Network is the leading omni channel pet care platform in southeast Europe, operating across Croatia, Romania, Slovenia, Serbia and Bulgaria. The transaction, terms of which were not disclosed, is expected to close in the third quarter of 2021.
Pet Network was created by TRG in 2018 through the acquisition and merger of three distinct businesses active in the pet supplies industry across southeast Europe: Pet Centar, which operates in Croatia, Serbia and Romania; Animax, which operates in Romania; and Mr. Pet, which operates in Slovenia. The origins of the group date back to 1999 when the first Pet Centar store was opened in Croatia. Today the Company operates more than 150 physical stores across five countries under the Pet Centar, Maxi Pet, Animax and Mr. Pet brands. The Company also operates various eCommerce channels as well as a growing offering of value-added services including veterinary pharmacies.
TRG Managing Directors Stepan Karpukhin and Harold Chatelus commented: “Pet Network is a fast growing and highly successful business that has benefitted from the global trends around pet humanization, combined with high levels of pet ownership across southeast Europe. The Company’s talented management team, led by CEO Ljiljana Markov Medugorac, has played a vital role in capitalizing on this positive momentum and will continue to run the business post the transaction closing.”
Colin Clark, Head of EMEA at TRG, added: “In line with TRG’s buy-and-build philosophy, during our ownership period, Pet Network has delivered remarkable growth and transformed into a sizeable business on a European scale. We are confident that AMCE is the right partner for Pet Network’s next chapter and are pleased to have found a like-minded investor to further the Company’s growth story.”
Ljiljana Markov Medugorac, CEO of Pet Network International commented: “TRG’s acquisition three years ago was an important milestone that helped us achieve rapid growth, add-on acquisitions, many new store openings, online expansion, an expanded own brands portfolio and countless other initiatives. Navigating through a global pandemic over the past year, we also expanded our operations to a new exciting market, Bulgaria. We are all proud of Pet Network's teams achievements, which were strongly backed up with TRG's support and guidance. While we will be sad to say goodbye to our colleagues at TRG, we are also excited to start the next chapter in the company’s development in partnership with AMCE, who like TRG share our vision for the company’s future growth.”
TRG CEO Nick Rohatyn added, “We are proud of our investment in Pet Network. This represents a landmark transaction for the European team as well as TRG globally. Given the strong growth drivers underpinning the pet space, TRG views this as a highly attractive sector. Our experience with Pet Network represents a great example of the innovative consumer focused businesses that can benefit from consolidation and pan-European scale that we like at TRG.”
TRG was advised on the transaction by William Blair (M&A), Deloitte (Financial & Tax), Baker McKenzie (Legal), Babic (Legal) and BCG (Commercial).
AMCE was advised by Houlihan Lokey and Alantra (M&A), Alvarez & Marsal (operations), Dickson Minto (Legal), EY (Financial & Tax), AT Kearney (Commercial).
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
AMCE is a London based, operationally growth focused European middle-market private equity firm. AMCE Fund I currently manages €650 million of committed capital and is part of A&M Capital, the global multi-strategy private equity firm managing in excess of €3 billion of capital. AMCE has an association with Alvarez & Marsal consulting (“A&M”) that enables AMCE to access the world class operational expertise of A&M’s almost 4,500 consultants across A&M’s 23 European offices and 65 offices globally. For more information, please visit www.a-mcapital.com/europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
The Rohatyn Group:
Julie Rudnick / Columbia Clancy
Sard Verbinnen & Co
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blackstone and Hudson Pacific Properties Announce Plans for New World-Class Film and TV Studios in the UK2.8.2021 09:00:00 CEST | Press release
Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005278/en/ Artist Impression No. 1 (Photo: Business Wire) Funds managed by Blackstone Real Estate Partners and Hudson Pacific Properties acquired a 91-acre site, 17 miles north of central London, through a joint venture for £120 million. The acquisition, with an expected total investment of over £700 million, will be the partners’ first expansion of their Sunset Studios platform outside of the US. The proposed development, which is subject to planning permission, would transform the site into one of the largest world-class film and television studio campuses. The project is expected to create over 4,500 permanent jobs for Broxbourne and the surrounding community and contribute more than £300 million annually int
AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies2.8.2021 08:00:00 CEST | Press release
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando. Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees. The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments. „I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, A
Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract2.8.2021 08:00:00 CEST | Press release
Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America. Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospi
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders2.8.2021 07:00:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210801005028/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas.1 Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use.1,2 Exicure’s SNAs provide distinct chemical and biochemical properties to oligonucleotides. I
Arqit Releases QuantumCloud™ to Deliver Stronger, Simpler Encryption2.8.2021 06:20:00 CEST | Press release
Arqit Limited (“Arqit”), a leader in quantum encryption technology announces the release of the first version of its service, QuantumCloud™ 1.0. This Platform‑as‑a‑Service software enables customers to secure the communications channels and data of any cloud, edge or end-point device. The service combines transformational and unique advances in both quantum and classical cryptography. The release of QuantumCloud™ 1.0 allows customers to secure devices globally by providing a strong device authentication capability, over which is layered the agreement of symmetric keys between authenticated and authorised devices. Importantly, since there are no asymmetric cryptographic primitives used within the trustless key agreement protocol, the keys can be regarded as safe against future attack using Shor’s algorithm running on a quantum computer. A range of other features will be added in future quarters, culminating in the launch of Arqit’s proprietary quantum satellites, which is targeted for 2
Arqit Registration Statement Related to Business Combination With Centricus Acquisition Corp. Declared Effective By SEC2.8.2021 06:04:00 CEST | Press release
Arqit Limited (“Arqit”), a leader in quantum encryption technology today announced the Registration Statement on Form F-4 in connection with the previously announced business combination (the “Business Combination”) with Centricus Acquisition Corp. (“Centricus”) (Nasdaq: CENHU, CENH, CENHUW), a publicly-listed special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (the “SEC”). Upon closing, the ordinary shares and warrants of Arqit Quantum Inc., a company formed for purposes of completing the Business Combination, will be listed on NASDAQ under the new ticker symbols “ARQQ” and “ARQQW.” The boards of directors of Arqit and Centricus have unanimously approved the Business Combination, and Centricus has set 9:00 a.m. ET on August 31, 2021 as the time and date for an extraordinary general meeting of shareholders to approve the proposals associated with the Business Combination. The proxy statement/prospectus contains important informatio
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie2.8.2021 01:30:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means including appealing the decision to the Irish courts. On November 28, 2018, Shire received a tax assessment from the Irish Revenue Commissioners for 398 million EUR. This assessment sought to tax a 1,635 million USD break fee Shire received from AbbVie in connection with the terminated offer to acquire Shire made by AbbVie in 2014. Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission. While Takeda is continuing to assess the substance of the decision, the company will record a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom